In a randomized controlled trial at three US hospitals over six months in 2021, the researchers randomized 30 attendings to prioritize seeing patients who were expected to be discharged that day before seeing other patients. Marisha Burden, MD, FACP, a professor of medicine and division head of hospital medicine at the University of Colorado School of Medicine in Aurora, and Angela Keniston, MSPH, an assistant professor and director of data and analytics for the division of hospital medicine at the University of Colorado School of Medicine, discuss the study’s findings.

Getting a handle on the biochemical processes that govern how food is broken down and used within the body can be a daunting task for many, and even for those who understand it, monitoring with technology isn’t always possible. This is where Levels come into play. An instant metabolic analysis just a few hours after eating is only the beginning of the Levels experience; the app focuses on four major blood glucose levers in a gamified experience: diet, exercise, stress, and sleep. Dr. Lauren Kelley-Chew, Levels’ Head of Clinical Product, discusses all of this and more.

The study was conducted while GLP-1 RAs and SGLT-2 inhibitors were still considered second-line therapies; however, in a 2022 Consensus Report, the American Diabetes Association and the European Association for the Study of Diabetes recommended these medications as first-line therapy for people with type 2 diabetes who have or are at high risk of certain complications such as heart failure, CKD, and atherosclerotic cardiovascular disease (ASCVD). Are the medications’ price tag keeping people away?

In a study of nearly 100,000 individuals aged 30 to 95 without any prior evidence of CVD, decline in peak metabolic equivalent of task score (METS) of greater than 1.0 was inversely proportionate to changes in mortality risk. METS were determined using symptom-limited exercise treadmill tests.

This 28-year-old man with hypertension and diabetes works two jobs, says he does not have time to exercise, takes most of his meals from fast-food restaurants, and is unhappy with his lifestyle. What would you recommend?

Based on cases reported to the CDC, this study reports an acceleration in case detection, with a dramatic increase in 2021. From 2019 to 2021, 17 states identified their first case of C auris; however, resistance to echinocandins increased threefold in 2021 compared to the previous two years. And because screening is not conducted uniformly across the United States, the true burden of C auris cases is likely higher than reported.